The Future of Pharmaceutical Innovation
Leveraging cutting-edge technology and AI-driven solutions to revolutionize drug discovery, development, and delivery for better patient outcomes.
About Us
At PDA Pharma, we bridge science and wellness by providing cutting-edge compounded formulations, especially tailored injectables that improve quality of life, metabolism, and cellular health. We serve licensed healthcare professionals and clinics with precision, compliance, and care.
NAD+ Pen
Experience the future of wellness with PDA Pharma’s NAD+ Pen — a revolutionary delivery system designed for rapid absorption and convenience. NAD+ supports cellular energy, improves mental clarity, promotes healthy aging, and boosts overall vitality. Trusted by health professionals, our NAD+ Pen helps you restore and maintain peak performance. Feel energized. Stay sharp. Live better.
Tirzepatide (GLP-1/GIP Agonist)
Tirzepatide is used for type 2 diabetes to help improve blood sugar levels. In type 2 diabetes, tirzepatide decreases blood sugar levels by helping release insulin when blood sugar levels are high, lowering the amount of sugar the liver makes, and slowing food movement through the intestines. Tizerpatide should be used together with diet and exercise.
Tizerpatide is FDA-approved to treat adults with type 2 diabetes and should be used together with diet and exercise. It can be used as a single therapy (on its own) or with other diabetes medicines, including sulfonylureas, SGLT2 inhibitors, or metformin.
It is not known if tirzepatide can be used in people who have had pancreatitis. Tirzepatide should not be used in people who have type 1 diabetes.
Our product is licensed under DMF 39900 type A
Retatrutide 40mg
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively.
The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF.
Here, in this randomized, double-blind, placebo-controlled trial, participants (n = 98) were randomly assigned to 48 weeks of once-weekly subcutaneous retatrutide (1, 4, 8 or 10mg dose) or placebo.